ORAGENICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ORAGENICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $96.00K.
- ORAGENICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-06-30 was $267.14K.
- ORAGENICS, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $363.14K, a 92.99% decline from fiscal 2020.
- ORAGENICS, INC. stock issued during period, value, stock options exercised for fiscal 2020 was $5.18M.
- ORAGENICS, INC. stock issued during period, value, stock options exercised for fiscal 2010 was $24.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2021-12-31 | $363.14K 10-K · filed 2023-04-17 | |
| 2021-09-30 | $96.00K 10-Q/A · filed 2023-04-14 | |
| 2021-06-30 | $267.14K 10-Q/A · filed 2023-04-14 | |
| 2020-12-31 | $5.18M 10-K/A · filed 2022-07-29 | |
| 2010-12-31 | $24.00K 10-K · filed 2012-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |